• About us
• Contact

Advertisement

Organisation › Details

Almirall Ltd.

Almirall is a global company based in Barcelona dedicated to providing valuable medicines through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated profitable growth allows us to devote our talent and efforts in the Dermatology area, with an additional interest in other specialist driven areas. Our size enables us to be agile and flexible so that we can accomplish the purpose of taking our innovative products wherever they are needed. Founded in 1943, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2014, its Total revenues totaled 1,407 million euros and, with more than 2,000 employees, it has gradually built up a trusted presence across Europe, as well as in the US and Mexico. *

 

	Start	2008-01-01 established?
	Group	Almirall (Group)
	Industry	dermatic
	Region	Uxbridge, Greater London
	Country	United Kingdom (GB)
	Street	4 The Square Stockley Park
	City	UB11 1ET Uxbridge
	Tel	+44-20-7160-2500
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Almirall (Group)

• [1] Almirall S.A.. (11/14/23). "Press Release: Almirall and Absci Announce AI Drug Discovery Partnership to Rapidly Develop Novel Treatments for Dermatological Diseases". Barcelona & Vancouver, WA....
• [2] Evotec SE. (5/19/22). "Press Release: Evotec and Almirall Enter into a Multi-target Alliance in Medical Dermatology". Hamburg & Barcelona....
• [3] Almirall S.A.. (12/14/21). "Press Release: Ichnos Sciences and Almirall Enter into a Licensing Agreement for First-in-Class IL-1RAP Antagonist Monoclonal Antibody". New York, NY & Barcelona....
• [4] Almirall S.A.. (2/17/21). "Press Release: Almirall and MC2 Therapeutics Enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora Cream for Treatment of Plaque Psoriasis". Barcelona & Copenhagen....
• [5] Almirall S.A.. (2/3/21). "Press Release: Almirall Announces Gianfranco Nazzi as New CEO"....
• [6] Almirall S.A.. (1/9/20). "Press Release: Almirall Signs a Strategic Agreement with 23andMe to License Rights of a Bispecific Monoclonal Antibody that Blocks All Three Isoforms of IL-36 Cytokine". Barcelona & Sunnyvale, CA....
• [7] Almirall S.A.. (1/9/20). "Press Release: Almirall and WuXi Biologics Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases". Barcelona....
• [8] Almirall S.A.. (1/9/20). "Press Release: Almirall Enters into an Option Agreement to Acquire Bioniz Therapeutics and to Establish a Broad Research Agreement to Further Expand Its Innovative Pipeline in Medical Dermatology". Barcelona....
• [9] Evotec AG. (9/17/18). "Press Release: Evotec and Almirall Enter into Research Collaboration in the Field of Dermatiological Diseases". Hamburg & Barcelona....
• [10] Locust Walk Partners, LLC. (7/11/18). "Press Release: Locust Walk Appoints Lubor Gaal as Senior Vice President and Head of Europe to Further Advance Global Expansion of Transactions Business". London & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.